Immunic, Inc. Announces Completion of Enrollment of Its Phase II CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis

Immunic, Inc. announced that the final patient has been enrolled and randomized in its phase II CALDOSE-1 trial of lead asset, IMU-838, the company’s selective oral DHODH inhibitor, in patients with moderate-to-severe ulcerative colitis.